Project description:Colitis-associated colorectal cancer (CAC), a subtype of colorectal cancer arising from chronic colonic inflammation, remains without specific therapeutic agents. Banxia-Xiexin decoction (BXD), a traditional Chinese medicine, is clinically used to treat gastritis and ulcerative colitis; however, its efficacy in CAC and associated mechanisms are not well understood. This study aimed to evaluate the therapeutic potential of BXD against CAC and explore its molecular mechanisms. A CAC mouse model was induced using azoxymethane/dextran sulfate sodium (AOM/DSS), and BXD was administered at vary-ing doses (0.95, 1.9, or 3.8 g/kg/day), alongside a sulfasalazine control. Therapeutic effica-cy was assessed by analyzing disease activity index, inflammatory markers, and histo-pathological changes. Additionally, 4D label-free proteomics and serum metabolomics were conducted to elucidate potential mechanisms. BXD significantly improved disease outcomes in CAC mice by reducing colonic inflammation and tumor hyperplasia, while lowering serum levels of TNF-α, IL-6, IL-1β, and IFN-γ. Metabolomic profiling suggested that BXD modulates valine, leucine, and isoleucine metabolism. Proteomic analysis re-vealed differentially expressed proteins (DEPs) enriched in complement and coagulation cascade pathways. Key DEPs (Fgg, Fgb, C3, and Cfh) were reversed by BXD treatment, which was confirmed at the mRNA level by qRT-PCR. In conclusion, BXD exerts protec-tive effects against CAC by regulating inflammatory responses and modulating amino acid metabolism and complement pathways. These findings provide novel insights into the pharmacological basis of BXD and support its potential clinical application in CAC therapy.
Project description:Chinese medicine is a complex system guided by traditional Chinese medicine (TCM) theories, which has proven to be especially effective in treating chronic and complex diseases. However, the underlying modes of action (MOA) are not always systematically investigated. Herein, a systematic study was designed to elucidate the multi-compound, multi-target and multi-pathway MOA of a Chinese medicine ,QSYQ, on myocardial infarction. Male Sprague Dawley rat model of myocardial infarction were administered QSYQ intragastrically for 7 days while the control group was not treated. The differentially expressed genes (DEGs) were identified from myocardial infarction rat model treated with QSYQ, followed by constructing a cardiovascular disease (CVD)-related multilevel compound-target-pathway network connecting main compounds to those DEGs supported by literature evidences and the pathways that are functionally enriched.
Project description:Using high-throughput antibody microarray, through cross-sectional sample detection and verification of samples that had undergone physical changes over time, it was found that people with balanced constitution and dampness constitution in Chinese medicine showed differences in serum protein expression. The differences were expressed as the level changes of 19 proteins such as Dectin-2, Siglec-7, AIF and TACI. The research results provided the basis for the scientific expression of traditional Chinese medicine (TCM) constitution.
Project description:Chemotherapy-induced peripheral neuropathy (CIPN) not only impacts chemotherapy regimens but also causes intolerable and long-lasting effects on cancer patients. Currently, duloxetine is the only drug used to treat CIPN. However, the clinical use of this drug still faces several challenges. Therefore, we focused on traditional Chinese medicine (TCM) to find an effective and safe alternative medicine. Huangqi Guizhi Wuwu Decoction (HGWD) is a traditional Chinese medicine that has been clinically used for treating nerve pain for thousands of years. This study aimed to investigate the neuroprotective effect of HGWD on cisplatin-induced injury in PC12 cells and to elucidate its potential mechanism of action.